NCT03513250View on ClinicalTrials.gov

Efficacy of Hyoscine-n-butylbromide in Catheter-related Bladder Discomfort After Elective Cesarean Section.

NACompletedINTERVENTIONAL
Enrollment

92

Participants

Timeline

Start Date

May 30, 2018

Primary Completion Date

July 1, 2020

Study Completion Date

July 15, 2020

Conditions
Catheter Related Bladder Discomfort
Interventions
DRUG

hyoscine-n-butylbromide

one ampoule of 20 mg of hyoscine-n-butylbromide (Buscopan, 20mg/Ampoule, CID/Boehringer ) will be administered intravenously immediately before the end of the cesarean section.

DRUG

control group

an equal volume(1 ml ) of normal saline will be administered before the end of cesarean section.

Trial Locations (1)

12944

Ahmed Ashour, Giza

All Listed Sponsors
lead

Cairo University

OTHER

NCT03513250 - Efficacy of Hyoscine-n-butylbromide in Catheter-related Bladder Discomfort After Elective Cesarean Section. | Biotech Hunter | Biotech Hunter